**IN THE CLAIMS:**

A marked-up version of the amended claims, with deletions indicated by bracketing and additions indicated by underlining, is included as Appendix A.

Please cancel claims 1-4, 7-9, 21 and 70 without prejudice.

Please amend claims 5, 6, 10-20, 71-74 and 85 to recite as follows:

5. (Amended) A compound having the structure:



or a pharmaceutically acceptable salt thereof, wherein:

A is $-(CH_2)_bCH=CH(CH_2)_c-$;

$R_1$ is aryl, heteroaryl or heterocycle fused to phenyl, each being optionally substituted with one to four substituents independently selected from $R_3$;

$R_2$ is $-R_3$, $-R_4$, $-(CH_2)_bC(=O)R_5$, $-(CH_2)_bC(=O)OR_5$, $-(CH_2)_bC(=O)NR_5R_6$, $-(CH_2)_bC(=O)NR_5(CH_2)_cC(=O)R_6$, $-(CH_2)_bNR_5C(=O)R_6$, $-(CH_2)_bNR_5C(=O)NR_6R_7$, $-(CH_2)_bNR_5R_6$, $-(CH_2)_bOR_5$, $-(CH_2)_bSO_dR_5$ or $-(CH_2)_bSO_2NR_5R_6$;

*a* is 1, 2, 3, 4, 5 or 6;

*b* and *c* are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4;

*d* is at each occurrence 0, 1 or 2;

$R_3$ is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl, $-C(=O)OR_8$, $-C(=O)R_8$, $-C(O)NR_8R_9$, $-C(=O)NR_8OR_9$, $-SO_2NR_8R_9$, $-NR_8SO_2R_9$, $-CN$, $-NO_2$, $-NR_8R_9$, -

$NR_8C(=O)R_9$, $-NR_8C(=O)(CH_2)_bOR_9$, $-NR_8C(=O)(CH_2)_bR_9$, $-O(CH_2)_bNR_8R_9$, or heterocycle fused to phenyl;

$R_4$ is alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, each being optionally substituted with one to four substituents independently selected from $R_3$, or $R_4$ is halogen or hydroxy;

$R_5$, $R_6$ and $R_7$ are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, wherein each of $R_5$, $R_6$ and $R_7$ are optionally substituted with one to four substituents independently selected from $R_3$; and

$R_8$ and $R_9$ are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or $R_8$ and $R_9$ taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of $R_8$, $R_9$, and $R_8$ and $R_9$ taken together to form a heterocycle are optionally substituted with one to four substituents independently selected from $R_3$.

Sub B1

Cont

6. (Amended) A compound having the structure:




or a pharmaceutically acceptable salt thereof, wherein:

A is $-(CH_2)_bC\equiv C(CH_2)_c-$;

$R_1$ is aryl, heteroaryl or heterocycle fused to phenyl, each being optionally substituted with one to four substituents independently selected from $R_3$;

$R_2$ is $-R_3$, $-R_4$, $-(CH_2)_bC(=O)R_5$, $-(CH_2)_bC(=O)OR_5$, $-(CH_2)_bC(=O)NR_5R_6$, $-(CH_2)_bC(=O)NR_5(CH_2)_cC(=O)R_6$, $-(CH_2)_bNR_5C(=O)R_6$, $-(CH_2)_bNR_5C(=O)NR_6R_7$, $-(CH_2)_bNR_5R_6$, $-(CH_2)_bOR_5$, $-(CH_2)_bSO_dR_5$ or $-(CH_2)_bSO_2NR_5R_6$;

*a* is 1, 2, 3, 4, 5 or 6;

*b* and *c* are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4;

*d* is at each occurrence 0, 1 or 2;

$R_3$ is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl, $-C(=O)OR_8$, $-C(=O)R_8$, $-C(O)NR_8R_9$, $-C(=O)NR_8OR_9$, $-SO_2NR_8R_9$, $-NR_8SO_2R_9$, -CN, $-NO_2$, $-NR_8R_9$, $-NR_8C(=O)R_9$, $-NR_8C(=O)(CH_2)_bOR_9$, $-NR_8C(=O)(CH_2)_bR_9$, $-O(CH_2)_bNR_8R_9$, or heterocycle fused to phenyl;

$R_4$ is alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, each being optionally substituted with one to four substituents independently selected from $R_3$, or $R_4$ is halogen or hydroxy;

$R_5$, $R_6$ and $R_7$ are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, wherein each of $R_5$, $R_6$ and $R_7$ are optionally substituted with one to four substituents independently selected from $R_3$; and

$R_8$ and $R_9$ are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or $R_8$ and $R_9$ taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of $R_8$, $R_9$, and $R_8$ and $R_9$ taken together to form a heterocycle are optionally substituted with one to four substituents independently selected from $R_3$.

10. (Amended) A compound having the structure:




or a pharmaceutically acceptable salt thereof, wherein:

A is a direct bond, $-(CH_2)_a-$, $-(CH_2)_bCH=CH(CH_2)_c-$, or $-(CH_2)_bC\equiv C(CH_2)_c-$;

$R_1$ is aryl, heteroaryl or heterocycle fused to phenyl, each being optionally substituted with one to four substituents independently selected from $R_3$;

$R_2$ is $-(CH_2)_bC(=O)R_5$;

*a* is 1, 2, 3, 4, 5 or 6;

*b* and *c* are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4;

*d* is at each occurrence 0, 1 or 2;

$R_3$ is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl, $-C(=O)OR_8$, $-C(=O)R_8$, $-C(O)NR_8R_9$, $-C(=O)NR_8OR_9$, $-SO_2NR_8R_9$, $-NR_8SO_2R_9$, $-CN$, $-NO_2$, $-NR_8R_9$, $-NR_8C(=O)R_9$, $-NR_8C(=O)(CH_2)_bOR_9$, $-NR_8C(=O)(CH_2)_bR_9$, $-O(CH_2)_bNR_8R_9$, or heterocycle fused to phenyl;

$R_4$ is alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, each being optionally substituted with one to four substituents independently selected from $R_3$, or $R_4$ is halogen or hydroxy;

$R_5$, $R_6$ and $R_7$ are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, wherein each of $R_5$, $R_6$ and $R_7$ are optionally substituted with one to four substituents independently selected from $R_3$; and

$R_8$ and $R_9$ are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or $R_8$ and $R_9$ taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of $R_8$, $R_9$, and $R_8$ and $R_9$ taken together to form a heterocycle are optionally substituted with one to four substituents independently selected from $R_3$.

11. (Amended) A compound having the structure:



or a pharmaceutically acceptable salt thereof, wherein:

A is a direct bond, $-(CH_2)_a-$, $-(CH_2)_bCH=CH(CH_2)_c-$, or $-(CH_2)_bC\equiv C(CH_2)_c-$;

$R_1$ is aryl, heteroaryl or heterocycle fused to phenyl, each being optionally substituted with one to four substituents independently selected from $R_3$;

$R_2$ is $-(CH_2)_bC(=O)NR_5R_6$;

*a* is 1, 2, 3, 4, 5 or 6;

*b* and *c* are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4;

*d* is at each occurrence 0, 1 or 2;

$R_3$ is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl, $-C(=O)OR_8$, $-C(=O)R_8$, $-C(O)NR_8R_9$, $-C(=O)NR_8OR_9$, $-SO_2NR_8R_9$, $-NR_8SO_2R_9$, $-CN$, $-NO_2$, $-NR_8R_9$, $-NR_8C(=O)R_9$, $-NR_8C(=O)(CH_2)_bOR_9$, $-NR_8C(=O)(CH_2)_bR_9$, $-O(CH_2)_bNR_8R_9$, or heterocycle fused to phenyl;

$R_4$ is alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, each being optionally substituted with one to four substituents independently selected from $R_3$, or $R_4$ is halogen or hydroxy;

$R_5$, $R_6$ and $R_7$ are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, wherein each of $R_5$, $R_6$ and $R_7$ are optionally substituted with one to four substituents independently selected from $R_3$; and

$R_8$ and $R_9$ are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or $R_8$

and $R_9$ taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of $R_8$, $R_9$, and $R_8$ and $R_9$ taken together to form a heterocycle are optionally substituted with one to four substituents independently selected from $R_3$.

12. (Amended) A compound having the structure:



or a pharmaceutically acceptable salt thereof, wherein:

A is a direct bond, $-(CH_2)_a-$, $-(CH_2)_bCH=CH(CH_2)_c-$, or $-(CH_2)_bC\equiv C(CH_2)_c-$;

$R_1$ is aryl, heteroaryl or heterocycle fused to phenyl, each being optionally substituted with one to four substituents independently selected from $R_3$;

$R_2$ is $-(CH_2)_bNR_5C(=O)R_6$;

*a* is 1, 2, 3, 4, 5 or 6;

*b* and *c* are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4;

*d* is at each occurrence 0, 1 or 2;

$R_3$ is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl, $-C(=O)OR_8$, $-C(=O)R_8$, $-C(O)NR_8R_9$, $-C(=O)NR_8OR_9$, $-SO_2NR_8R_9$, $-NR_8SO_2R_9$, $-CN$, $-NO_2$, $-NR_8R_9$, $-NR_8C(=O)R_9$, $-NR_8C(=O)(CH_2)_bOR_9$, $-NR_8C(=O)(CH_2)_bR_9$, $-O(CH_2)_bNR_8R_9$, or heterocycle fused to phenyl;

$R_4$ is alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, each being optionally substituted with one to four substituents independently selected from $R_3$, or $R_4$ is halogen or hydroxy;

$R_5$, $R_6$ and $R_7$ are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, wherein each of $R_5$, $R_6$ and $R_7$ are optionally substituted with one to four substituents independently selected from $R_3$; and

$R_8$ and $R_9$ are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or $R_8$ and $R_9$ taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of $R_8$, $R_9$, and $R_8$ and $R_9$ taken together to form a heterocycle are optionally substituted with one to four substituents independently selected from $R_3$.

B2

13. (Amended) A compound having the structure:




A2 Cont

or a pharmaceutically acceptable salt thereof, wherein:

A is a direct bond, $-(CH_2)_a-$, $-(CH_2)_bCH=CH(CH_2)_c-$, or $-(CH_2)_bC\equiv C(CH_2)_c-$;

$R_1$ is aryl, heteroaryl or heterocycle fused to phenyl, each being optionally substituted with one to four substituents independently selected from $R_3$;

$R_2$ is $-(CH_2)_bNR_5R_6$;

*a* is 1, 2, 3, 4, 5 or 6;

*b* and *c* are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4;

*d* is at each occurrence 0, 1 or 2;

$R_3$ is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl, $-C(=O)OR_8$, $-C(=O)R_8$, $-C(O)NR_8R_9$, -

$C(=O)NR_8OR_9$, $-SO_2NR_8R_9$, $-NR_8SO_2R_9$, -CN, $-NO_2$, $-NR_8R_9$, $-NR_8C(=O)R_9$, $-NR_8C(=O)(CH_2)_bOR_9$, $-NR_8C(=O)(CH_2)_bR_9$, $-O(CH_2)_bNR_8R_9$, or heterocycle fused to phenyl;

$R_4$ is alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, each being optionally substituted with one to four substituents independently selected from $R_3$, or $R_4$ is halogen or hydroxy;

$R_5$, $R_6$ and $R_7$ are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, wherein each of $R_5$, $R_6$ and $R_7$ are optionally substituted with one to four substituents independently selected from $R_3$; and

$R_8$ and $R_9$ are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or $R_8$ and $R_9$ taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of $R_8$, $R_9$, and $R_8$ and $R_9$ taken together to form a heterocycle are optionally substituted with one to four substituents independently selected from $R_3$.

14. (Amended) A compound having the structure:




or a pharmaceutically acceptable salt thereof, wherein:

A is a direct bond, $-(CH_2)_a-$, $-(CH_2)_bCH=CH(CH_2)_c-$, or $-(CH_2)_bC\equiv C(CH_2)_c-$;

$R_1$ is aryl, heteroaryl or heterocycle fused to phenyl, each being optionally substituted with one to four substituents independently selected from $R_3$;

$R_2$ is $R_4$;

*a* is 1, 2, 3, 4, 5 or 6;

*b* and *c* are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4;

*d* is at each occurrence 0, 1 or 2;

$R_3$ is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl, $-C(=O)OR_8$, $-C(=O)R_8$, $-C(O)NR_8R_9$, $-C(=O)NR_8OR_9$, $-SO_2NR_8R_9$, $-NR_8SO_2R_9$, -CN, $-NO_2$, $-NR_8R_9$, $-NR_8C(=O)R_9$, $-NR_8C(=O)(CH_2)_bOR_9$, $-NR_8C(=O)(CH_2)_bR_9$, $-O(CH_2)_bNR_8R_9$, or heterocycle fused to phenyl;

$R_4$ is alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, each being optionally substituted with one to four substituents independently selected from $R_3$, or $R_4$ is halogen or hydroxy;

$R_5$, $R_6$ and $R_7$ are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, wherein each of $R_5$, $R_6$ and $R_7$ are optionally substituted with one to four substituents independently selected from $R_3$; and

$R_8$ and $R_9$ are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or $R_8$ and $R_9$ taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of $R_8$, $R_9$, and $R_8$ and $R_9$ taken together to form a heterocycle are optionally substituted with one to four substituents independently selected from $R_3$.

15. (Amended) A compound having the structure:




or a pharmaceutically acceptable salt thereof, wherein:

A is a direct bond, $-(CH_2)_a-$, $-(CH_2)_bCH=CH(CH_2)_c-$, or $-(CH_2)_bC\equiv C(CH_2)_c-$;

$R_1$ is aryl, heteroaryl or heterocycle fused to phenyl, each being optionally substituted with one to four substituents independently selected from $R_3$;

$R_2$ is $R_4$;

*a* is 1, 2, 3, 4, 5 or 6;

*b* and *c* are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4;

*d* is at each occurrence 0, 1 or 2;

$R_3$ is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl, $-C(=O)OR_8$, $-C(=O)R_8$, $-C(O)NR_8R_9$, $-C(=O)NR_8OR_9$, $-SO_2NR_8R_9$, $-NR_8SO_2R_9$, -CN, $-NO_2$, $-NR_8R_9$, $-NR_8C(=O)R_9$, $-NR_8C(=O)(CH_2)_bOR_9$, $-NR_8C(=O)(CH_2)_bR_9$, $-O(CH_2)_bNR_8R_9$, or heterocycle fused to phenyl;

$R_4$ is substituted alkyl;

$R_5$, $R_6$ and $R_7$ are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, wherein each of $R_5$, $R_6$ and $R_7$ are optionally substituted with one to four substituents independently selected from $R_3$; and

$R_8$ and $R_9$ are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or $R_8$ and $R_9$ taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of $R_8$, $R_9$, and $R_8$ and $R_9$ taken together to form a heterocycle are optionally substituted with one to four substituents independently selected from $R_3$.

16. (Amended) A compound having the structure:




or a pharmaceutically acceptable salt thereof, wherein:

A is a direct bond, $-(CH_2)_a-$, $-(CH_2)_bCH=CH(CH_2)_c-$, or $-(CH_2)_bC\equiv C(CH_2)_c-$;

$R_1$ is aryl, heteroaryl or heterocycle fused to phenyl, each being optionally substituted with one to four substituents independently selected from $R_3$;

$R_2$ is $R_4$;

*a* is 1, 2, 3, 4, 5 or 6;

*b* and *c* are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4;

*d* is at each occurrence 0, 1 or 2;

$R_3$ is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl, $-C(=O)OR_8$, $-C(=O)R_8$, $-C(O)NR_8R_9$, $-C(=O)NR_8OR_9$, $-SO_2NR_8R_9$, $-NR_8SO_2R_9$, -CN, $-NO_2$, $-NR_8R_9$, $-NR_8C(=O)R_9$, $-NR_8C(=O)(CH_2)_bOR_9$, $-NR_8C(=O)(CH_2)_bR_9$, $-O(CH_2)_bNR_8R_9$, or heterocycle fused to phenyl;

$R_4$ is substituted arylalkyl;

$R_5$, $R_6$ and $R_7$ are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, wherein each of $R_5$, $R_6$ and $R_7$ are optionally substituted with one to four substituents independently selected from $R_3$; and

$R_8$ and $R_9$ are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or $R_8$ and $R_9$ taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of $R_8$, $R_9$, and $R_8$ and $R_9$ taken together to form a heterocycle are optionally substituted with one to four substituents independently selected from $R_3$.

17. (Amended) A compound having the structure:



or a pharmaceutically acceptable salt thereof, wherein:

A is a direct bond, $-(CH_2)_a-$, $-(CH_2)_bCH=CH(CH_2)_c-$, or $-(CH_2)_bC\equiv C(CH_2)_c-$;

$R_1$ is aryl, heteroaryl or heterocycle fused to phenyl, each being optionally substituted with one to four substituents independently selected from $R_3$;

$R_2$ is $R_4$;

*a* is 1, 2, 3, 4, 5 or 6;

*b* and *c* are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4;

*d* is at each occurrence 0, 1 or 2;

$R_3$ is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl, $-C(=O)OR_8$, $-C(=O)R_8$, $-C(O)NR_8R_9$, $-C(=O)NR_8OR_9$, $-SO_2NR_8R_9$, $-NR_8SO_2R_9$, -CN, $-NO_2$, $-NR_8R_9$, $-NR_8C(=O)R_9$, $-NR_8C(=O)(CH_2)_bOR_9$, $-NR_8C(=O)(CH_2)_bR_9$, $-O(CH_2)_bNR_8R_9$, or heterocycle fused to phenyl;

$R_4$ is substituted heterocycle;

$R_5$, $R_6$ and $R_7$ are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, wherein each of $R_5$, $R_6$ and $R_7$ are optionally substituted with one to four substituents independently selected from $R_3$; and

$R_8$ and $R_9$ are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or $R_8$ and $R_9$ taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of $R_8$, $R_9$, and $R_8$ and $R_9$ taken together to form a heterocycle are optionally substituted with one to four substituents independently selected from $R_3$.

18. (Amended) A compound having the structure:



or a pharmaceutically acceptable salt thereof, wherein:

A is a direct bond, $-(CH_2)_a-$, $-(CH_2)_bCH=CH(CH_2)_c-$, or $-(CH_2)_bC\equiv C(CH_2)_c-$;

$R_1$ is aryl, heteroaryl or heterocycle fused to phenyl, each being optionally substituted with one to four substituents independently selected from $R_3$;

$R_2$ is $R_4$;

*a* is 1, 2, 3, 4, 5 or 6;

*b* and *c* are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4;

*d* is at each occurrence 0, 1 or 2;

$R_3$ is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl, $-C(=O)OR_8$, $-C(=O)R_8$, $-C(O)NR_8R_9$, $-C(=O)NR_8OR_9$, $-SO_2NR_8R_9$, $-NR_8SO_2R_9$, $-CN$, $-NO_2$, $-NR_8R_9$, $-NR_8C(=O)R_9$, $-NR_8C(=O)(CH_2)_bOR_9$, $-NR_8C(=O)(CH_2)_bR_9$, $-O(CH_2)_bNR_8R_9$, or heterocycle fused to phenyl;

$R_4$ is 3-triazolyl, optionally substituted at its 5-position with:

(a) a $C_1$-$C_4$ straight or branched chain alkyl group optionally substituted with a hydroxyl, methylamino, dimethylamino or 1-pyrrolidinyl group; or

(b) a 2-pyrrolidinyl group;

$R_5$, $R_6$ and $R_7$ are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, wherein each of $R_5$, $R_6$ and $R_7$ are optionally substituted with one to four substituents independently selected from $R_3$; and

$R_8$ and $R_9$ are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or $R_8$ and $R_9$ taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of $R_8$, $R_9$, and $R_8$ and $R_9$ taken together to form a heterocycle are optionally substituted with one to four substituents independently selected from $R_3$.

19. (Amended) A compound having the structure:




or a pharmaceutically acceptable salt thereof, wherein:

A is a direct bond, $-(CH_2)_a-$, $-(CH_2)_bCH=CH(CH_2)_c-$, or $-(CH_2)_bC\equiv C(CH_2)_c-$;

$R_1$ is aryl, heteroaryl or heterocycle fused to phenyl, each being optionally substituted with one to four substituents independently selected from $R_3$;

$R_2$ is $R_4$;

*a* is 1, 2, 3, 4, 5 or 6;

*b* and *c* are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4;

*d* is at each occurrence 0, 1 or 2;

$R_3$ is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl, $-C(=O)OR_8$, $-C(=O)R_8$, $-C(O)NR_8R_9$, $-C(=O)NR_8OR_9$, $-SO_2NR_8R_9$, $-NR_8SO_2R_9$, $-CN$, $-NO_2$, $-NR_8R_9$, $-NR_8C(=O)R_9$, $-NR_8C(=O)(CH_2)_bOR_9$, $-NR_8C(=O)(CH_2)_bR_9$, $-O(CH_2)_bNR_8R_9$, or heterocycle fused to phenyl;

$R_4$ is tetrazole;

$R_5$, $R_6$ and $R_7$ are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, wherein each of $R_5$, $R_6$ and $R_7$ are optionally substituted with one to four substituents independently selected from $R_3$; and

$R_8$ and $R_9$ are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or $R_8$ and $R_9$ taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of $R_8$, $R_9$, and $R_8$ and $R_9$ taken together to form a heterocycle are optionally substituted with one to four substituents independently selected from $R_3$.

B3 Cont

20. (Amended) A compound having the structure:




or a pharmaceutically acceptable salt thereof, wherein:

A is a direct bond, $-(CH_2)_a-$, $-(CH_2)_bCH=CH(CH_2)_c-$, or $-(CH_2)_bC\equiv C(CH_2)_c-$;

$R_1$ is aryl, heteroaryl or heterocycle fused to phenyl, each being optionally substituted with one to four substituents independently selected from $R_3$;

$R_2$ is $R_4$;

*a* is 1, 2, 3, 4, 5 or 6;

*b* and *c* are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4;

*d* is at each occurrence 0, 1 or 2;

$R_3$ is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl, $-C(=O)OR_8$, $-C(=O)R_8$, $-C(O)NR_8R_9$, $-C(=O)NR_8OR_9$, $-SO_2NR_8R_9$, $-NR_8SO_2R_9$, $-CN$, $-NO_2$, $-NR_8R_9$, -

$NR_8C(=O)R_9$, $-NR_8C(=O)(CH_2)_bOR_9$, $-NR_8C(=O)(CH_2)_bR_9$, $-O(CH_2)_bNR_8R_9$, or heterocycle fused to phenyl;

$R_4$ is imidazole;

$R_5$, $R_6$ and $R_7$ are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, wherein each of $R_5$, $R_6$ and $R_7$ are optionally substituted with one to four substituents independently selected from $R_3$; and

$R_8$ and $R_9$ are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or $R_8$ and $R_9$ taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of $R_8$, $R_9$, and $R_8$ and $R_9$ taken together to form a heterocycle are optionally substituted with one to four substituents independently selected from $R_3$.

71. (Amended) A compound having the structure:



or a pharmaceutically acceptable salt thereof, wherein:

A is a direct bond, $-(CH_2)_a-$, $-(CH_2)_cCH=CH(CH_2)_c-$, or $-(CH_2)_bC\equiv C(CH_2)_c-$;

$R_1$ is aryl, heteroaryl or heterocycle fused to phenyl, each being optionally substituted with one to four substituents independently selected from $R_3$;

$R_2$ is $-(CH_2)_bC(=O)NR_5R_6$, $-(CH_2)_bNR_5C(=O)R_6$, 3-triazolyl or 5-tetrazolyl;

*a* is 1, 2, 3, 4, 5 or 6;

*b* is 0;

*c* is at each occurrence 0, 1, 2, 3 or 4;

*d* is at each occurrence 0, 1 or 2;

$R_3$ is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl,

heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl, $-C(=O)OR_8$, $-C(=O)R_8$, $-C(O)NR_8R_9$, $-C(=O)NR_8OR_9$, $-SO_2NR_8R_9$, $-NR_8SO_2R_9$, -CN, $-NO_2$, $-NR_8R_9$, $-NR_8C(=O)R_9$, $-NR_8C(=O)(CH_2)_bOR_9$, $-NR_8C(=O)(CH_2)_bR_9$, $-O(CH_2)_bNR_8R_9$, or heterocycle fused to phenyl;

$R_4$ is alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, each being optionally substituted with one to four substituents independently selected from $R_3$, or $R_4$ is halogen or hydroxy;

$R_5$, $R_6$ and $R_7$ are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, wherein each of $R_5$, $R_6$ and $R_7$ are optionally substituted with one to four substituents independently selected from $R_3$; and

$R_8$ and $R_9$ are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or $R_8$ and $R_9$ taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of $R_8$, $R_9$, and $R_8$ and $R_9$ taken together to form a heterocycle are optionally substituted with one to four substituents independently selected from $R_3$.

B4
Cont

72. (Amended) A compound having the structure:




or a pharmaceutically acceptable salt thereof, wherein:

A is a direct bond, $-(CH_2)_a-$, $-(CH_2)_bCH=CH(CH_2)_c-$, or $-(CH_2)_bC\equiv C(CH_2)_c-$;

$R_1$ is aryl, heteroaryl or heterocycle fused to phenyl, each being optionally substituted with one to four substituents independently selected from $R_3$;

$R_2$ is 3-triazolyl or 5-tetrazolyl;

*a* is 1, 2, 3, 4, 5 or 6;

*b* and *c* are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4;

*d* is at each occurrence 0, 1 or 2;

$R_3$ is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl, $-C(=O)OR_8$, $-C(=O)R_8$, $-C(O)NR_8R_9$, $-C(=O)NR_8OR_9$, $-SO_2NR_8R_9$, $-NR_8SO_2R_9$, $-CN$, $-NO_2$, $-NR_8R_9$, $-NR_8C(=O)R_9$, $-NR_8C(=O)(CH_2)_bOR_9$, $-NR_8C(=O)(CH_2)_bR_9$, $-O(CH_2)_bNR_8R_9$, or heterocycle fused to phenyl;

$R_4$ is alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, each being optionally substituted with one to four substituents independently selected from $R_3$, or $R_4$ is halogen or hydroxy;

$R_5$, $R_6$ and $R_7$ are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, wherein each of $R_5$, $R_6$ and $R_7$ are optionally substituted with one to four substituents independently selected from $R_3$; and

$R_8$ and $R_9$ are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or $R_8$ and $R_9$ taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of $R_8$, $R_9$, and $R_8$ and $R_9$ taken together to form a heterocycle are optionally substituted with one to four substituents independently selected from $R_3$.

73. (Amended) A compound having the structure:




or a pharmaceutically acceptable salt thereof, wherein:

-A-$R_1$ is phenyl, optionally substituted with one to four substituents independently selected from halogen, alkoxy, $-NR_8C(=O)R_9$, $-C(=O)NR_8R_9$, and $-O(CH_2)_bNR_8R_9$, wherein *b* is 2 or 3;

$R_2$ is $-(CH_2)_bC(=O)NR_5R_6$, $-(CH_2)_bNR_5C(=O)R_6$, 3-triazolyl or 5-tetrazolyl, wherein *b* is 0;

*a* is 1, 2, 3, 4, 5 or 6;

*c* is at each occurrence 0, 1, 2, 3 or 4;

*d* is at each occurrence 0, 1 or 2;

$R_3$ is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl, $-C(=O)OR_8$, $-C(=O)R_8$, $-C(O)NR_8R_9$, $-C(=O)NR_8OR_9$, $-SO_2NR_8R_9$, $-NR_8SO_2R_9$, -CN, $-NO_2$, $-NR_8R_9$, $-NR_8C(=O)R_9$, $-NR_8C(=O)(CH_2)_bOR_9$, $-NR_8C(=O)(CH_2)_bR_9$, $-O(CH_2)_bNR_8R_9$, or heterocycle fused to phenyl;

$R_4$ is alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, each being optionally substituted with one to four substituents independently selected from $R_3$, or $R_4$ is halogen or hydroxy;

$R_5$, $R_6$ and $R_7$ are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, wherein each of $R_5$, $R_6$ and $R_7$ are optionally substituted with one to four substituents independently selected from $R_3$; and

$R_8$ and $R_9$ are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or $R_8$ and $R_9$ taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of $R_8$, $R_9$, and $R_8$ and $R_9$ taken together to form a heterocycle are optionally substituted with one to four substituents independently selected from $R_3$.

74. (Amended) A compound having the structure:



or a pharmaceutically acceptable salt thereof, wherein:

$-A-R_1$ is phenyl, optionally substituted with one to four substituents independently selected from halogen, alkoxy, $-NR_8C(=O)R_9$, $-C(=O)NR_8R_9$, and $-O(CH_2)_bNR_8R_9$;

$R_2$ is 3-triazolyl or 5-tetrazolyl;

*a* is 1, 2, 3, 4, 5 or 6;

*b* is 2 or 3;

*c* is at each occurrence 0, 1, 2, 3 or 4;

*d* is at each occurrence 0, 1 or 2;

$R_3$ is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl, $-C(=O)OR_8$, $-C(=O)R_8$, $-C(O)NR_8R_9$, $-C(=O)NR_8OR_9$, $-SO_2NR_8R_9$, $-NR_8SO_2R_9$, $-CN$, $-NO_2$, $-NR_8R_9$, $-NR_8C(=O)R_9$, $-NR_8C(=O)(CH_2)_bOR_9$, $-NR_8C(=O)(CH_2)_bR_9$, $-O(CH_2)_bNR_8R_9$, or heterocycle fused to phenyl;

$R_4$ is alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, each being optionally substituted with one to four substituents independently selected from $R_3$, or $R_4$ is halogen or hydroxy;

$R_5$, $R_6$ and $R_7$ are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, wherein each of $R_5$, $R_6$ and $R_7$ are optionally substituted with one to four substituents independently selected from $R_3$; and

$R_8$ and $R_9$ are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or $R_8$ and $R_9$ taken together with the atom or atoms to which they are

bonded form a heterocycle, wherein each of $R_8$, $R_9$, and $R_8$ and $R_9$ taken together to form a heterocycle are optionally substituted with one to four substituents independently selected from $R_3$.

85. (Amended) A compound having the structure:



or a pharmaceutically acceptable salt thereof, wherein:

A is a direct bond, $-(CH_2)_a-$, $-(CH_2)_bCH=CH(CH_2)_c-$, or $-(CH_2)_bC\equiv C(CH_2)_c-$;

$R_1$ is aryl, heteroaryl or heterocycle fused to phenyl, each being optionally substituted with one to four substituents independently selected from $R_3$;

$R_2$ is $R_4$;

*a* is 1, 2, 3, 4, 5 or 6;

*b* and *c* are the same or different and at each occurrence independently selected from 0, 1, 2, 3 or 4;

*d* is at each occurrence 0, 1 or 2;

$R_3$ is at each occurrence independently halogen, hydroxy, carboxy, alkyl, alkoxy, haloalkyl, acyloxy, thioalkyl, sulfinylalkyl, sulfonylalkyl, hydroxyalkyl, aryl, substituted aryl, arylalkyl, substituted arylalkyl, heterocycle, substituted heterocycle, heterocyclealkyl, substituted heterocyclealkyl, $-C(=O)OR_8$, $-C(=O)R_8$, $-C(O)NR_8R_9$, $-C(=O)NR_8OR_9$, $-SO_2NR_8R_9$, $-NR_8SO_2R_9$, $-CN$, $-NO_2$, $-NR_8R_9$, $-NR_8C(=O)R_9$, $-NR_8C(=O)(CH_2)_bOR_9$, $-NR_8C(=O)(CH_2)_bR_9$, $-O(CH_2)_bNR_8R_9$, or heterocycle fused to phenyl;

$R_4$ is 3-triazolyl, optionally substituted at its 5-position with:

(a) methyl, n-propyl, isopropyl, 1-hydroxyethyl, 3-hydroxypropyl, methylaminomethyl, dimethylaminomethyl, 1-(dimethylamino)ethyl, 1-pyrrolidinylmethyl or 2-pyrrolidinyl;

$R_5$, $R_6$ and $R_7$ are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle or heterocyclealkyl, wherein each of $R_5$, $R_6$ and $R_7$ are optionally substituted with one to four substituents independently selected from $R_3$; and

$R_8$ and $R_9$ are the same or different and at each occurrence independently hydrogen, alkyl, aryl, arylalkyl, heterocycle, or heterocyclealkyl, or $R_8$ and $R_9$ taken together with the atom or atoms to which they are bonded form a heterocycle, wherein each of $R_8$, $R_9$, and $R_8$ and $R_9$ taken together to form a heterocycle are optionally substituted with one to four substituents independently selected from $R_3$.

Please add new claims 88-117 to recite as follows:

88. (New) A composition comprising the compound of claim 5 and a pharmaceutically acceptable carrier.

89. (New) A composition comprising the compound of claim 6 and a pharmaceutically acceptable carrier.

90. (New) A composition comprising the compound of claim 10 and a pharmaceutically acceptable carrier.

91. (New) A composition comprising the compound of claim 11 and a pharmaceutically acceptable carrier.

92. (New) A composition comprising the compound of claim 12 and a pharmaceutically acceptable carrier.

93. (New) A composition comprising the compound of claim 13 and a pharmaceutically acceptable carrier.

94. (New) A composition comprising the compound of claim 14 and a pharmaceutically acceptable carrier.

95. (New) A composition comprising the compound of claim 15 and a pharmaceutically acceptable carrier.

96. (New) A composition comprising the compound of claim 16 and a pharmaceutically acceptable carrier.

97. (New) A composition comprising the compound of claim 17 and a pharmaceutically acceptable carrier.

98. (New) A composition comprising the compound of claim 18 and a pharmaceutically acceptable carrier.

99. (New) A composition comprising the compound of claim 19 and a pharmaceutically acceptable carrier.

100. (New) A composition comprising the compound of claim 20 and a pharmaceutically acceptable carrier.

101. (New) A composition comprising the compound of claim 71 and a pharmaceutically acceptable carrier.

102. (New) A composition comprising the compound of claim 72 and a pharmaceutically acceptable carrier.

103. (New) A composition comprising the compound of claim 73 and a pharmaceutically acceptable carrier.

104. (New) A composition comprising the compound of claim 74 and a pharmaceutically acceptable carrier.

105. (New) A composition comprising the compound of claim 85 and a pharmaceutically acceptable carrier.

106. (New) A compound of claim 6, wherein the compound is: 3-(2-phenylethynyl)-1H-indazole-5-carboxamide, or a pharmaceutically acceptable salt thereof.

107. (New) A compound of claim 10, wherein the compound is:
3-(4-fluorophenyl)-1H-indazole-5-carboxylic acid;
1-{(3-(4-fluorophenyl)-1H-indazol-5-yl)carbonyl} piperidine-4-carboxylic acid;
3-(4-fluorophenyl)(1H-indazol-5-yl) pyrrolidinyl ketone;
3-(4-fluorophenyl)(1H-indazol-5-yl)piperazinyl ketone;
1-(3-(4-fluorophenyl)-1H-indazol-5-yl)-2-phenylethan-1-one;
1-(3-(4-fluorophenyl)-1H-indazol-5-yl)ethan-1-one; or a pharmaceutically acceptable salt thereof.

108. (New) A compound of claim 11, wherein the compound is:
3-(4-fluorophenyl)-1H-indazole-5-carboxamide;
(3-(4-fluorophenyl)(1H-indazol-5-yl))-N-benzamide;
N-(2-(dimethylamino)ethyl)3-(4-fluorophenyl)(1H-indazol-5-yl))carboxamide;
ethyl 1-{(3-(4-fluorophenyl)-1H-indazol-5-yl)carbonyl}piperidine-4-carboxylate;
methyl 4-{(3-(4-fluorophenyl)-1H-indazol-5-yl)carbonylamino}benzoate;
4-{3-(4-fluorophenyl)-1H-indazol-5-yl)carbonylamino}benzoic acid;
4-{(3-(4-fluorophenyl)-1H-indazole-5-yl)carbonylamino}benzamide;
(3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(2-pyridyl)carboxamide;
(3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(3-pyridyl)carboxamide;
(3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(4-pyridyl)carboxamide;
tert-butyl 3-{(3-(4-fluorophenyl)-1H-indazol-5-yl)carbonylamino)propanoate;
(3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(3-hydroxyphenyl)carboxamide;
3-{(3-(4-fluorophenyl)-1H-Indazol-5-yl)carbonylamino)propanoic acid;
(3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(3-nitrophenyl)carboxamide;
tert-butyl-2-{(3-(4-fluorophenyl)-1H-indazol-5-yl)carbonylamino}acetate;
4-{(3-(4-fluorophenyl)-1H-indazol-5-yl)carbonylamino} butanoic acid;
N-(3-aminophenyl)(3-(4-fluorophenyl)(1H-indazol-5-yl))carboxamide;
2-{(3-(4-fluorophenyl)-1H-indazol-5-yl)carbonylamino}acetic acid;
5-{(3-(4-fluorophenyl)-1H-indazol-5-yl)carbonylamino}pentanoic acid;

4-({(3-(4-fluorophenyl)-1H-indazol-5-yl)carbonylamino}methyl)benzoic acid;

(3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(4-pyridylmethyl)carboxamide;

2-(4-{(3-(4-fluorophenyl)-1H-indazol-5-yl)carbonylamino}phenyl)acetic acid;

(3-(4-fluorophenyl)(1H-indazol-5-yl))-N,N-dimethylcarboxamide;

(3-(4-fluorophenyl)(1H-indazol-5-yl))-N-methylcarboxamide;

N-(3-aminoethyl)(3-(4-fluorophenyl)(1H-indazol-5-yl))carboxamide;

N-(3-aminopropyl)(3-(4-fluorophenyl)(1H-indazol-5-yl))carboxamide;

(3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(2-hydroxypropyl)carboxamide;

N-(2H-1,2,3,4-tetrazol-5-yl)(3-(4-fluorophenyl)(1H-indazol-5-yl))carboxamide;

(3-(4-fluorophenyl)(1H-indazol-5-yl)}-N-(3-morpholin-4-ylpropyl)carboxamide;

(3-(4-fluorophenyl)(1H-indazol-5-yl)}-N-(3-pyridylmethyl)carboxamide;

(3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(2-(1-methylimidazol-5-yl)ethyl)carboxamide);

(3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(2-pyridylmethyl)carboxamide;

N-(2-carbamoylethyl)(3 -(4-fluorophenyl)(1H-indazol-5-yl))carboxamide;

N-(3-carbamoylpropyl)(3-(4-fluorophenyl)(1H-indazol-5-yl))carboxamide;

A5

1-(3-(4-fluorophenyl)-1H-indazol-5-yl)-2-phenylethan-1-one;

3-(4-methoxyphenyl)-1H-indazole-5-carboxamide;

3-(4-hydroxyphenyl)-1H-indazole-5-carboxamide;

3-(2-naphthyl)-1H-indazole-5-carboxamide;

3-benzo(b)thiophen-2-yl-1H-indazole-5-carboxamide;

3-benzo(d)furan-2-yl-1H-indazole-5-carboxamide;

3-(3-(methylethyl)phenyl)-1H-indazole-5-carboxamide;

3-(4-(dimethylamino)phenyl)-1H-indazole-5-carboxamide;

3-(3-furyl)-1H-indazole-5-carboxamide;

3-{4-(2-(dimethylamino)ethoxy)phenyl}-1H-indazole-5-carboxamide;

3-(3,4-dimethoxyphenyl)-1H-indazole-5-carboxamide;

3-(3-aminophenyl)-1H-indazole-5-carboxamide;

3-(2H-benzo(d)1,3-dioxolen-5-yl)-1H-indazole-5-carboxamide;

(3-benzo(d)furan-2-yl(1H-indazol-5-yl))-N-(methylethyl)carboxamide;

(3-benzo(d)furan-2-yl(1H-indazol-5-yl))-N-(2-methoxyethyl)carboxamide;

(3-benzo(d)furan-2-yl(1H-indazol-5-yl))-N-(2-(dimethylamino)ethyl)carboxamide;

(3-benzo(d)furan-2-yl(1H-indazol-5-yl))-N-(4-(dimethylamino)butyl)carboxamide;

(3-benzo(d)furan-2-yl(1H-indazol-5-yl))-N-(3-(dimethylamino)propyl)carboxamide;

(3-benzo(d)furan-2-yl(1H-indazol-5-yl))-N-(2-methylpropyl)carboxamide;

(3-benzo(d)furan-2-yl(1H-indazol-5-yl))-N-methylcarboxamide;

3-(3-(3-pyridylcarbonylamino)phenyl)-1H-indazole-5-carboxamide;

3-(3-(2-methoxyacetylamino)phenyl)-1H-indazole-5-carboxamide;

3-(3-(4-piperidylcarboxyamino)phenyl)-1H-indazole-5-carboxamide;

(1S)-1-{N-(3-(5-carbamoyl(1H-indazol-3-yl))phenyl)carbamoyl}ethyl acetate;

3-{3-(2-methoxyethyl)amino)phenyl}-1H-indazole-5-carboxamide;

3-(3-(3-piperidylpropanoylamino)phenyl)-1H-indazole-5-carboxamide;

3-(3-(2-furylcarbonylamino)phenyl)-1H-indazole-5-carboxamide;

3-{3-(2-(dimethylamino)acetylamino)phenyl}-1H-indazole-5-carboxamide;

3-(3-(2-phenylacetylamino)phenyl)-1H-Indazole-5-carboxamide;

A5 cont

3-{3-(2-(4-methoxyphenyl)acetylamino)phenyl}-1H-indazole-5-carboxamide;

3-{3-(2-(2-methyl-1,3-thiazol-5-yl)acetylamino)phenyl}-1H-indazole-5-carboxamide;

3-(3-(oxolan-3yl-carbonylamino)phenyl)-1H-indazole-5-carboxamide;

3-(3-(2-(3-thienyl)acetylamino)phenyl)-1H-indazole-5-carboxamide;

3-(3-(2-thienylcarbonylamino)phenyl)-1H-indazole-5-carboxamide;

3-(3-(2-(4-pyridyl)acetylamino)phenyl)-1H-Indazole-5-carboxamide;

3-(3-(2-(2-pyridyl)acetylamino)phenyl)-1H-Indazole-5-carboxamide;

3-{3-(2-(4-fluorophenyl)acetylamino)phenyl}-1H-indazole-5-carboxamide;

3-(3-(cyclopropylcarbonylamino)phenyl)-1H-indazole-5-carboxamide;

3-{3-((3-hydroxyphenyl)carbonylamino)phenyl}-1H-indazole-5-carboxamide;

3-{3-(2-(2,4-dichlorophenyl)acetylamino)phenyl}-1H-indazole-5-carboxamide;

3-(3-{2-(4-(trifluoromethyl)phenyl)acetylamino}phenyl)-1H-indazole-5-carboxamide;

3-(3-{2-(4-(dimethylamino)phenyl)acetylamino}phenyl)-1H-indazole-5-carboxamide;

3-{3-(2-(2-chloro-4-fluorophenyl) acetylamino)phenyl}-1H-indazole-5-carboxamide;

3-{3-(2-(4-chlorophenyl)acetylamino)phenyl}-1H-indazole-5-carboxamide;

3-(3-(3-phenylpropanoylamino)phenyl)-1H-indazole-5-carboxamide;

3-{3-(3-(4-fluorophenyl)propanoylamino)phenyl}-1H-indazole-5-carboxamide;

3-{3-(2-(3,4-difluorophenyl)acetylamino)phenyl}-1H-indazole-5-carboxamide;

3-{3-(2-(2-fluorophenyl) acetylamino)phenyl}-1H-indazole-5-carboxamide;

3-(3-(2-phenylpropanoylamino)phenyl}-1H-indazole-5-carboxamide;

3-(3-(2-piperidylethoxy)phenyl}-1H-indazole-5-carboxamide;

N-ethyl-3-{(3-(4-fluorophenyl)(1H-indazol-5-yl))carbonylamino} propanamide;

(3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(3-methoxypropyl)carboxamide;

3-{3-(N-(2-piperidylethyl)carbamoyl)phenyl}-1H-indazole-5-carboxamide;

(3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(2-hydroxyethyl)carboxamide;

(3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(3-hydroxypropyl)carboxamide;

(3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(2-methoxyethyl)carboxamide;

(3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(oxolan-2-ylmethyl)carboxamide;

A5 Cont

3-(2H, 3H-benzo(e)1,4-dioxin-6-yl)-1H-indazole-5-carboxamide;

3-(3-quinolyl)-1H-indazole-5-carboxamide;

3-(6-methoxy-2-naphthyl)-1H-indazole-5-carboxamide;

3-(2,3-dihydrobenzo(b)furan-5-yl)-1H-indazole-5-carboxamide;

(3-(4-fluorophenyl)(1H-indazol-5-yl))-N-(3-oxo-3-pyrrolidinylpropyl) carboxamide;

3-{(3-(4-fluorophenyl)(1H-indazol-5-yl))carbonylamino}-N-methyl propanamide;

3-{(3-(4-fluorophenyl)(1H-indazol-5-yl))carbonylamino}-N,N-dimethyl propanamide;

3-{(3-(4-fluorophenyl)(1H-indazol-5-yl))carbonylamino}-N-(2-methoxyethyl)propanamide; or a pharmaceutically acceptable salt thereof.

Sub B7

109. (New) A compound of claim 12, wherein the compound is:

phenyl-N-(3-phenyl(1H-indazol-5-yl))carboxamide;

N-(3-phenyl(1H-indazol-5-yl))-2-pyridylcarboxamide;

methyl 4-(N-(3-phenyl-1H-indazol-5-yl)carbamoyl)benzoate;

4-(N-(3-phenyl-1H-indazol-5-yl)carbamoyl)benzoic acid;

(2-hydroxyphenyl)-N-(3-phenyl(1H-indazol-5-yl)carboxamide;

N-(3-(phenyl-1H-indazole-5-yl))acetamide;

(4-aminophenyl)-N-(3-phenyl(1H-indazol-5-yl))carlboxamide;

(3-aminophenyl)-N-(3-phenyl(1H-indazol-5-yl))carboxamide;

N-(3-(4-fluorophenyl)(1H-indazol-5-yl)) (2-methylphenyl)carboxamide;

N-(3-(4-fluorophenyl)(1H-indazol-5-yl))(2-methoxyphenyl)carboxamide;

N-(3-(4-fluorophenyl)(1H-indazol-5-yl))(4-phenylphenyl)carboxamide;

benzo(b)thiophen-2-yl-N-(3-(4-fluorophenyl)(1H-indazol-5-yl))carboxamide;

methyl 4-{N-(3-(4-fluorophenyl)-1H-indazol-5-yl)carbamoyl}benzoate;

N-(3-(4-fluorophenyl)(1H-indazol-5-yl))-2-pyridylcarboxamide;

4-{N-(3-(4-fluorophenyl)-1H-indazol-5-yl)carbamoyl}benzoic acid;

cyclopropyl-N-(3-(4-fluorophenyl)(1H-indazol-5-yl))carboxamide;

methyl 4-{N-(3-(4-fluorophenyl)(1H-indazol-5-yl))-N-methylcarbamoyl}benzoate;

4-{N-(3-fluorophenyl)(1H-indazol-5-yl))-N-methylcarbamoyl}benzoic acid;

methyl 3-{N-((4-fluorophenyl)-1H-indazol-5-yl}carbamoyl}benzoate;

3-{N-(3-(4-fluorophenyl)-1H-indazol-5-yl)carbamoyl}benzoic acid;

N-(3-(4-fluorophenyl)-(1H-indazol-5-yl))(4-(N-methylcarbamoyl)phenyl)carboxamide;

4-{N-(3-(4-fluorophenyl)-1H-indazol-5-yl)carbamoyl}benzamide;

1-4-{N-(3-(4-methoxyphenyl)-1H-indazol-5-yl)carbamoyl}benzoic acid;

4-(N-(3-(4-pyridyl)-1H-indazol-5-yl)carbamoyl)benzoic acid;

N-(3-(4-fluorophenyl)(1H-indazol-5-yl)benzamide;

(3,4-bis(trifluoromethyl)phenyl)-N-(3-(4-fluorophenyl)(1H-indazol-5-yl))carboxamide;

N-(3-(4-fluorophenyl)(1H-indazol-5-yl))-2-furylcarboxamide;

N-(3-(4-fluorophenyl)(1H-indazol-5-yl))(3,4-dichlorophenyl)carboxamide;

N-(3-(4-fluorophenyl)(1H-indazol-5-yl))(2-hydroxyphenyl)carboxamide;

2-{N-(3-(4-fluorophenyl)-1H-indazol-5-yl)carbamoyl}phenyl)methyl benzoate;

N-(3-(4-fluorophenyl)(1H-indazol-5-yl))-4-pyridylcarboxamide;

N-(3-(4-fluorophenyl)(1H-indazol-5-yl))-3-pyridylcarboxamide;

N-(3-(4-fluorophenyl)(1H-indazol-5-yl))-2-thienylcarboxamide;

N-(3-(4-fluorophenyl)(1H-indazol-5-yl))morpholin-4-yl-carboxamide;

N-(3-(4-fluorophenyl)(1H-indazol-5-yl))((4-fluorophenyl)amino)carboxamide;

N-((2R)-2-hydroxycyclohexyl)methyl) (3-(4-fluorophenyl) (1H-indazol-5-yl))carboxamide; or a pharmaceutically acceptable salt thereof.

110. (New) A compound of claim 13, wherein the compound is:

(3-(4-fluorophenyl)(1H-indazol-5-yl))(4-pyridylmethyl)amine;

(3-(4-fluorophenyl)(1H-indazol-5-yl))(3-pyridylmethyl)amine; or a pharmaceutically acceptable salt thereof.

111. (New) A compound of claim 14, wherein the compound is:

3-phenyl-5-trifluoromethyl-1H-indazole;

5-fluoro-3-phenyl-1H-indazole;

5-nitro-3-phenyl-1H-indazole;

5-amino-3-phenyl-1H-indazole;

3-phenyl-1H-indazol-5-ol;

5-methyl-3-phenyl-1H-indazole;

3-(4-fluorophenyl)-5-pyrazol-3-yl-1H-indazole;

5-benzimidazol-2-yl-3-(4-fluorophenyl)-1H-indazole;

5-{3-(4-fluorophenyl)(1H-indazole-5-yl))-3-phenyl-4H-1,2,4-triazole;

2-{5-(3-(4-fluorophenyl)-1H-indazol-5-yl)-4H-1,2,4-triazol-3-yl} furan;

5-(3-(4-fluorophenyl)(1H-indazol-5-yl))-3-(4-pyridyl)-4H-1,2,4-triazole;

3-(4-chlorophenyl)-5-(3-(4-fluorophenyl)(1H-indazol-5-yl))-4H-1,2,4-triazole;

5-(3-(4-fluorophenyl)(1H-indazole-5-yl))-3-(4-nitrophenyl)-4H-1,2,4-triazole;

1-{5-(3-(4-fluorophenyl)(1H-indazol-5-yl))(4H-1,2,4-triazol-3-yl))-4-methoxybenzene;

4-{5-(3-(4-fluorophenyl)-1H-indazol-5-yl)-4H-1,2,4-triazol-3-yl}phenylamine;

5-(3-(4-fluorophenyl)(1H-indazol-5-yl))-3-benzyl-4H-1,2,4-triazole;

2-(3-(4-fluorophenyl)(1H-indazol-5-yl))-5-phenyl-1,3,4-oxadiazole;

5-(3-(4-fluorophenyl)(1H-indazol-5-yl))-2-methyl-1,3,4-oxadiazole;

ethyl (2E)-3-(3-(4-fluorophenyl)-1H-indazol-5-yl)prop-2-enoate;

3-(3-(4-fluorophenyl)-1H-indazol-5-yl)propanoic acid;

5-(3-(4-fluorophenyl)(1H-indazol-5-yl))-3-(3-pyridyl)-4H- 1,2,4-triazole;

4-{5-(3-(4-fluorophenyl)-1H-indazol-5-yl)-4H-1,2,4-triazol-3-yl} phenol;

2-{5-(3-(4-fluorophenyl)1H-indazol-5-yl)-4H-1,2,4-triazol-3-yl}acetic acid;

ethyl-3-{5-{3-(4-fluorophenyl)-1H-indazol-5-yl)-4H-1,2,4-triazol-3-yl}propanoate;

ethyl-4-{5-(3-(4-fluorophenyl)-1H-indazol-5-yl}-4H-1,2,4-triazol-3-yl}butanoate;

3-{5-(3-(4-fluorophenyl)-1H-indazol-5-yl)-4H-1,2,4-triazol-3-yl}propanoic acid;

5-methyl-3-(4-fluorophenyl)-1H-indazole;

3-(3-(4-fluorophenyl)-1H-indazol-5-yl)-1,2,4-oxadiazolin-5-one; or a pharmaceutically acceptable salt thereof.

112. (New) A compound of claim 15, wherein the compound is:

3-(4-fluorophenyl)-5-(2-phenylethynyl)-1H-indazole;

5-((1E)-2-phenylvinyl)-3-(4-fluorophenyl)-1H-indazole;

5-((1E)-2-(2-pyridyl)vinyl)-3-(4-fluorophenyl)-1H-indazole;

4-{(1E)-2-((3-(4-fluorophenyl)-1H-indazol-5-yl)vinyl}benzoic acid;

5-((1E)-2-(3-nitrophenyl)vinyl)-3-(4-fluorophenyl)-1H-indazole;

5-((1Z)-2-phenylvinyl)-3-(4-fluorophenyl)-1H-indazole;

5-((1E)-2-(4-aminophenyl)vinyl)-3-(4-fluorophenyl)-1H-indazole;

5-((1E)-2-(4-pyridyl)vinyl)-3-(4-fluorophenyl)-1H-indazole;

(2E)-3-(3-(4-fluorophenyl)-1H-indazol-5-yl)prop-2-enoic acid;

5-(2-(3-aminophenyl)ethyl)-3-(4-fluorophenyl)-1H-indazole;

4-{2-(3-(4-fluorophenyl)-1H-indazol-5-yl)ethyl}benzoic acid;

3-(4-fluorophenyl)-5-(2-(2-pyridyl)ethyl)-1H-indazole;

3-(4-fluorophenyl)-5-(2-phenylethyl)-1H-indazole;

1-(3-(4-fluorophenyl)-1H-indazol-5-yl)-2-phenylethan-1-ol; or a pharmaceutically acceptable salt thereof.

113. (New) A compound of claim 17, wherein the compound is:

5-amino-3-(3,4-dimethoxyphenyl)-1H-indazole trifluoroacetate;

5-amino-3-(4-methoxyphenyl)-1H-indazole hydrochloride;

3-(3-(trifluoromethyl)phenyl)-1H-indazol-5-yl-amin;

3-(4-fluorophenyl)-1H-indazol-5-yl-amine;

ethyl(3-(4-fluorophenyl)(1H-indazol-5-yl))amine;

4-(3-(4-fluorophenyl)-1H-indazole-5-yl)pyrimidine-2-yl-amine;

5-(3-(4-fluorophenyl)-1H-indazol-5-yl)-4H-1,2,4-triazole-3-yl-amine;

1-({5-(3-(4-fluorophenyl)-1H-indazol-5-yl)-4H-1,2,4-triazol-3-yl}methyl)piperidin-4-ol;

1-acetyl-4-({5-(3-(4-fluorophenyl)(1H-indazol-5-yl))(4H-1,2,4-triazol-3-yl)}methyl) piperazine;

3-(3-(4-fluorophenyl)(1H-indazol-5-yl))-5-(piperidylmethyl)-1H-1,2,4-triazole;

4-({3-(3-(4-fluorophenyl)(1H-indazol-5-yl))-1H-1,2,4-triazol-5-yl}methyl)morpholine;

4-({5-(3-(4-fluorophenyl)-1H-indazol-5-yl)-1,3,4-oxadiazol-2-yl}methyl)morpholine;

1-({3-(3-(4-fluorophenyl)-1H-indazol-5-yl)-1H-1,2,4-triazol-5-yl}methyl)pyrrolidine-2-one;

(5-(3-(4-fluorophenyl)-1H-indazol-5-yl)-1H-1,2,4-triazol-3-yl)methan-1-ol;

3-(3-(4-fluorophenyl)(1H-indazol-3-yl))-5-((4-pyrrolidinylpiperidyl) methyl)-1H-1,2,4-triazole; or a pharmaceutically acceptable salt thereof.

114. (New) A compound of claim 18, wherein the compound is:

3-(3-(4-fluorophenyl)-1H-indazol-5-yl)-1H-1,2,4-triazole;

5-(3-(4-fluorophenyl)(1H-indazole-5-yl))-3-methyl-4H-1,2,4-triazole;

1-{5-(3-(4-fluorophenyl)-1H-indazole-5-yl)-4H-1,2,4-triazol-3-yl} propan-2-ol;

5-(3-(4-fluorophenyl)(1H-indazol-5-yl))-3-propyl-4H-1,2,4-triazole;

5-{3-(3-(methylethyl)phenyl)-1H-indazol-5-yl}-1H-1,2,4-triazole;

4-(5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl)phenol;

(4-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)dimethylamine;

3-(3-((1E)-2-phenylvinyl)-1H-indazol-5-yl)-1H-1,2,4-triazole;

{2-(4-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenoxy)ethyl}dimethylamine;

3-(5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl)furan;

1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-4-methoxybenzene;

5-(3-naphthyl-1H-indazol-5-yl)-1H-1,2,4-triazole;

3-(5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl)thiophene;

5-(3-(2-naphthyl)-1H-indazol-5-yl)-1H-1,2,4-triazole;

3-(5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl)phenylamine;

3-(3-(3,4-dichlorophenyl)-1H-indazol-5-yl)-1H-1,2,4-triazole;

3-(5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl)benzo(b)thiophene;

3-(3-(4-methylphenyl)-1H-indazol-5-yl)-1H-1,2,4-triazole;

N-(3-(5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl)phenyl)acetamide;

5-(3-(3-chlorophenyl)-1H-indazol-5-yl)-1H-1,2,4-triazole;

1-((1E)-2-(5-(1H-1,2,4-triazol-3-yl)((1H-indazol-3-yl))vinyl)-4-methoxybenzene;

3-{3-((1E)-2-(4-chlorophenyl)vinyl)-1H-indazol-5-yl}-1H-1,2,4-triazole;

2-(5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl)benzo(b)furan;

1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-4-(methylsulfonyl)benzene;

3-{3-((1E)-2-(4-methylphenyl)vinyl)-1H-indazol-5-yl}-1H-1,2,4-triazole;

1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-4-(methylsulfinyl)benzene;

5-(5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl)-2H-benzo(d)1,3-dioxolene;

4-(5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl)phenylamine;

5-{3-(4-(trifluoromethyl)phenyl)-1H-indazol-5-yl}-1H-1,2,4-triazole;

(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl)) phenyl) (methylsulfonyl)amine;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-methoxyacetamide;

N-(3-(5-( 1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-phenylacetamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-furylcarboxamide;

5-(3-(2-phenylethynyl)-1H-indazol-5-yl)-1H-1,2,4-triazole;

N-(3-(5-( 1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-3-pyridylcarboxamide;

1-{5-{3-(4-fluorophenyl)1H-indazol-5-yl}-4H-1,2,4-Triazol-3-yl}ethan-1-ol;

1-{5-(3-(4-fluorophenyl)-1H-indazol-5-yl}-4H-1,2,4-triazol-3-yl}propan-2-ol;

{3-(3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenoxy)propyl}dimethylamine;

{2-(3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenoxy)ethyl} dimethylamine;

1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-3-(2-morpholin-4-yl-ethoxy)benzene;

1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-3-(2-pyrrolidinylethoxy) benzene;

1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-3-(2-piperidylethoxy) benzene;

1-{2-(3-(5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl)phenoxy)ethyl} pyrrolidin-2-one;

1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-3-(2-piperazinylethoxy) benzene;

1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-3-(3-piperdylpropoxy) benzene;

4-{2-(3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenoxy)ethyl}-1-acetylpiperazine;

N-{2-(3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenoxy)ethyl}(phenylmethoxy) carboxamide;

2-(3-(5-(1H-1,2,4-triazol-5-yl)-1H-indazol-3-yl)phenoxy)ethylamine;

1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-3-(2-cyclohexylethoxy) benzene;

1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-3-(2-azaperhyroepinylethoxy)benzene;

N-(4-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-2-furyl caroxamide;

(3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-N-benzyl caroxamide;

N-{2-(3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl)phenoxy)ethyl}acetamide;

5-(3-(2-chlorophenyl)-1H-indazol-3-yl)-1H-1,2,4-triazole;

(3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-N-(2,2-dimehtylpropyl)carboxamide;

(3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-N-(cyclopropylmethyl)carboxamide; (3-(5-(1H-1,2,4-trizol-5-yl)(1H-indazol-3-yl))phenyl)-N-(3-pyridylmethyl)carboxamide;

(3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-4-methyl piperazinyl ketone;

(3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-N-((4-fluorophenyl)methyl) carboxamide;

(3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-N-indan-2-ylcarboxamide;

(3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-N-((1R)indanyl)carboxamide;

(3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-N-((1S)indanyl)carboxamide;

(3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-N-((1S,2R)-2-hydroxyindanyl)carboxamide;

(3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-N-((2S,1R)-2-hydroxyindanyl)carboxamide;

(3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-N-(1-methyl-1-phenylethyl)carboxamide;

(3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-N-(tert-butyl)carboxamide;

(3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-N-((1R)-1-phenylethyl)carboxamide;

1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-3-(2-piperidylethoxy) benzene;

(3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl-isoindolin-2-yl ketone;

(3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-N-(2-(dimethylamino)ethyl)carboxamide;

1-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))-3-(2-piperidylethoxy) benzene;

(3-(5-(1H-1,2,4-triazol-5-yl)(1H-indazol-3-yl))phenyl)-N-(1R)indanyl benzene;

{5-(3-(4-fluorophenyl)-1H-indazol-5-yl)-4H-(1,2,4)-triazol-3-ylmethyl}-dimethyl-amine;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-3-piperidylpropanamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-hydroxypropanamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-(dimethylamino)acetamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl)phenyl)butanamide;

2E-N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-3-phenylprop-2-enamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-phenoxypropanamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-3,3-dimethylbutanamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)cyclopropylcarboxamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-indol-3-yl-2-oxoacetamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)(6-chloro(3-pyridyl))carboxamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)cyclopentylcarboxamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)methane carboxylic acid;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)benzo(b)thiophen-2-carboxamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-pyridylcarboxamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-3-furylcarboxamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-hydroxy-2-phenylacetamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)isoxazol-5-ylcarboxamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-(2-furyl)-2-oxoacetamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-oxo-2-phenylacetamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)pentanamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-4-pyridylcarboxamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-cyclohexylacetamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-3-propanamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-(4-fluorophenyl)acetic acid;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)(2R)-2-hydroxy-2-phenylacetamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)(2S)-2-hydroxy-2-phenylacetamide;

(2-{3-(3-(4-fluorophenyl)(1H-indazol-5-yl))(1H-1,2,4-triazol-5-yl)}ethyl)dimethylamine;

diethyl({3-(3-(4-fluorophenyl)(1H-indazol-5-yl))(1H-1,2,4-triazol-5-yl)}methyl)amine;

4-({3-(3-(4-fluorophenyl)(1H-indazol-5-yl))-1H-1,2,4-triazol-5-yl}methyl)morpholine;

4-({5-(3-(4-fluorophenyl)-1H-indazol-5-yl)-1,3,4-oxadiazol-2-yl}methyl)morpholine;

1-({3-(3-(4-fluorophenyl)-1H-indazol-5-yl)-1H-1,2,4-triazol-5-yl}methyl)pyrrolidine-2-one;

({3-(3-(4-fluorophenyl)(1H-indazol-5-yl))(1H-1,2,4-triazol-5-yl)}methyl)methylamine;

({3-(3-(4-fluorophenyl)(1H-indazol-5-yl))(1H-1,2,4-triazol-5-yl)}ethyl)dimethylamine;

(2R)-N-(3-(5-{5-((dimethylamino)methyl)(1H-1,2,4-triazol-3-yl)}(1H-indazol-3-yl))phenyl)-2-hydroxy-2-phenylacetamide;

N-(3-(5-{5-((dimethylamino)methyl)(1H-1,2,4-triazol-3-yl)}(1H-indazol-3-yl))phenyl)-3,3-dimethylbutanamide;

3-(3-(4-fluorophenyl)(1H-indazol-5-yl))-5-(pyrrolidinylmethyl)-1H-1,2,4-triazole;

N-(3-(5-{5-((dimethylamino)methyl)(1H-1,2,4-triazol-3-yl)}(1H-indazol-3-yl))phenyl)-3-methylbutanamide;

N-(3-(5-{5-((dimethylamino)methyl)(1H-1,2,4-triazol-3-yl)}(1H-indazol-3-yl))phenyl)-3-pyridylcarboxamide;

(3-(5-{5-((dimethylamino)methyl)(1H-1,2,4-triazol-3-yl)}(1H-indazol-3-yl))phenyl)-N-((4-fluorophenyl)methyl)carboxamide;

(3-(5-{5-((dimethylamino)methyl)(1H-1,2,4-triazol-3yl)}(1H-indazol-3-yl))phenyl)-N-((*tert*-butyl)methyl)carboxamide;

((1R)indanyl)(3-(5-{5-((dimethylamino)methyl)(1H-1,2,4-triazol-3-yl)}(1H-indazol-3-yl))phenyl)carboxamide;

({3-(3-(4-methoxyphenyl)(1H-indazol-5-yl))(1H-1,2,4-triazol-5-yl)}methyl)dimethylamine;

{(3-(3-(2H-benzo(d)1,3-dioxolen-5-yl))(1H-indazol-5-yl))(1H-1,2,4-triazol-5-yl)}methyl}dimethylamine;

(3-(5-(3-((dimethylamino)methyl)(1H-1,2,4-triazol-5-yl))(1H-indazol-3-yl))phenyl)-N-(2-piperidylethyl)carboxamide;

(3-(5-(3-((dimethylamino)methyl)(1H-1,2,4-triazol-5-yl))(1H-indazol-3-yl))phenyl)-N-cyclobutylcarboxamide·2HCl;

1-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl)-3-(2-methoxyethoxy)benzene;

1-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl)-3-(3-pyridylmethoxy)benzene;

3-(5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl)benzoic acid N-(4-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-(3-pyridyl)acetamide;

N-(4-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-phenylacetamide;

N-(4-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-methoxyacetamide;

N-(4-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-(dimethylamino)acetamide;

(4-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)(methylsulfonyl)amine;

(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-N-(2-methoxyethyl)carboxamide;

(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-N-benzamide;

(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-N-(2-phenethyl)carboxamide;

(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl-N-(2-piperidylethyl)carboxamide;

(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl-N-(2-morpholin-4-ylethyl)carboxamide;

(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl-N-cyclohexylcarboxamide;

(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl-N-cyclopentylcarboxamide;

(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl-N-(4-fluorophenyl)carboxamide;

(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl-N-{2-(1-benzyl(4-piperidyl))ethylcarboxamide;

(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl-N-((1R,2R)-2-phenylcyclopropyl) carboxamide;

(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl-N-cyclopropylcarboxamide;

(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl-N-(3-pyridyl)carboxamide;

(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl-N-(5,6,7,8-tetrahydronaphthyl)carboxamide;

(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl-N-(1-benzyl(4-piperidyl))carboxamide;

(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl-N-(1-benzylpyrrolidin-3-yl)carboxamide;

(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl-N-(methylethyl)carboxamide;

(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl-N-cyclobutylcarboxamide;

(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl-N-(4-pyridyl)carboxamide;

6-(5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl)-2H,3h-benzo(e)1,4-dioxin;

6-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))-2-methoxynaphthalene;

3-(3-(3-quinoyl)-1H-indazol-5-yl)-1H-1,2,4-triazole;

5-(5-(1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl)-2,3-dihydrobenzo(b)furan;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)benzamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)(2,4-dichlorophenyl)carboxamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)(4-methoxyphenyl)carboxamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)(4-methylphenyl)carboxamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)(4-chlorophenyl)carboxamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-methylpropanamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-3-methylbutanamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-morpholin-4-yl-acetamide;

N-(3-(5-(1H-1,2,4-triazol-3-yl)(1H-indazol-3-yl))phenyl)-2-(4-methylpiperazinyl)acetamide;

3-(3-(4-fluorophenyl)(1H-indazol-3-yl))-5-(pyrrolidinylmethyl)-1H-1,2,4-triazole;

({3-(3-(6-methoxy(2-naphthyl))(1H-indazol-5-yl))(1H-1,2,4-triazol-5-yl)}methyl)dimethylamine;

2-methoxy-6-{5-(5-(pyrrolidinylmethyl)(1H-1,2,4-triazol-3-yl))(1H-indazol-3-yl)}naphthalene;

N-phenyl(3-{5-(5-(pyrrolidinylmethyl)(1H-1,2,4-triazol-3-yl))(1H-indazol-3-yl)}phenyl)carboxamide;

6-{5-(5-(pyrrolidinylmethyl)-1H-1,2,4-triazol-3-yl)-1H-indazol-3-yl}-2H,3h-benzo(e)1,4-dioxin; or a pharmaceutically acceptable salt thereof.

115. (New) A compound of claim 19, wherein the compound is:

5-(3-(4-fluorophenyl)-1H-indazol-5-yl)-2H-1,2,3,4-tetrazole;

1-(5-(2H-1,2,3,4-tetrazol-5-yl)(1H-indazol-3-yl))-2-methoxybenzene;

5-(1E)-2-phenylvinyl)-1H-indazole-5yl)-2H-1,2,3,4-tetrazole;

5-(3-(3-pyridyl)-1H-indazol-5-yl)-2H-1,2,3,4-tetrazole;

2-(5-(2H-1,2,3,4-tetrazol-5-yl)-1H-indazol-3-yl)thiophene;

5-{3-(4-(methylethyl)phenyl)-1H-indazol-5-yl}-2H-1,2,3,4-tetrazole;

2-(5-(2H-1,2,3,4-tetrazol-5-yl)-1H-indazol-3-yl)furan;

3-(5-(2H-1,2,3,4-tetrazol-5-yl)-1H-indazol-3-yl)phenylamine;

5-(5-(1H-1,2,3,4-tetraazol-5-yl)-1H-indazol-3-yl)-2H-benzo(d)1,3-dioxolene;

3-(5-(2H-1,2,3,4-tetrazol-5-yl)-1H-indazol-3-yl)thiophene;

5-(3-(2-naphthyl)-1H-indazol-5-yl)-1H-1,2,3,4-tetrazole;

1-(5-(1H-1,2,3,4-tetraazol-5-yl)(1H-indazol-3-yl))-4-methoxybenzene;

1-(5-(1H-1,2,3,4-tetraazol-5-yl)(1H-indazol-3-yl))-4-(2-methylpropoxy)benzene;

5-(3-(4-chlorophenyl)-1H-indazol-5-yl)-2H-1,2,3,4-tetrazole;

1-(5-(2H-1,2,3,4-tetrazol-5-yl)(1H-indazol-3-yl))-3-methoxybenzene;

5-(3-(4-pyridyl)-1H-indazol-5-yl)-2H-1,2,3,4-tetrazole;

2-(5-(2H-1,2,3,4-tetraazol-5-yl)-1H-indazol-3-yl)benzo(b)furan;

2-(5-(2H-1,2,3,4-tetrazol-5-yl)-1H-indazol-3-yl)phenol;

3-(5-(2H-1,2,3,4-tetrazol-5-yl)-1H-indazol-3-yl)phenol;

5-(3-(2-phenylethynyl)-1H-indazol-5-yl)-1H-1,2,3,4-tetrazole;

5-(3-(2-phenylethyl)-1H-indazol-5-yl)-2H-1,2,3,4-tetrazole;

5-{3-(3-(methylethyl)phenyl)-1H-indazol-5-yl}-1H-1,2,4-triazole;

N-(3-(5-(2H-1,2,3,4-tetrazol-5-yl)(1H-indazol-3-yl))phenyl)-2-methoxyacetamide;

2-(5-(1H-1,2,3,4-tetraazol-5-yl)-1H-indazol-3-yl)benzo(b)thiophene;

1-(5-(1H-1,2,3,4-tetraazol-5-yl)(1H-indazol-3-yl))-4-(2-morpholin-4-ylethoxy)benzene;

N-(3-(5-2H-1,2,3,4-tetrazol-5-yl)(1H-indazol-3-yl))phenyl)2-phenoxypropanamide;

N-(3-(5-(2H-1,2,3,4-tetrazol-5-yl)(1H-indazol-3-yl))phenyl)-3-piperidylpropanamide;

N-(3-(5-(2H-1,2,3,4-tetrazol-5-yl)(1H-indazol-3-yl))phenyl)-2-furylcarboxamide;

1-(5-(1H-1,2,3,4-tetraazol-5-yl)(1H-indazol-3-yl))-3-(2-morpholin-4-ylethoxy)benzene;

4-(5-(2H-1,2,3,4-tetraazol-5-yl)(1H-indazol-3-yl))-1,2-dimethoxybenzene;

N-(3-(5-(2H-1,2,3,4-tetrazol-5-yl)(1H-indazol-3-yl))phenyl)-3-methoxypropanamide;

N-(3-(5-(2H-1,2,3,4-tetrazol-5-yl)(1H-indazol-3-yl))phenyl)-3-pyridylcarboxamide;

{3-(4-(5-(1H-1,2,3,4-tetrazo-5-yl)(1H-indazol-3-yl))phenoxy)propyl}dimethylamine;

{3-(3-(5-(1H-1,2,3,4-tetrazol-5-yl)(1H-indazol-3-yl))phenoxy)propyl}dimethylamine;

{2-(3-(5-(1H-1,2,3,4-tetrazol-5-yl)(1H-indazol-3-yl))phenoxy)ethyl}dimethylamine;

N-(3-(5-(2H-1,2,3,4-tetrazol-5-yl)(1H-indazol-3-yl))phenyl)(2S)-2-hydroxypropanamide;

(1S)-1-{N-(3-(5-(2H-1,2,3,4-tetrazol-5-yl)(1H-indazol-3-yl))phenyl)carbamoyl}ethyl acetate;

N-(4-(5-(2H-1,2,3,4-tetrazo-5-yl)(1H-indazol-3-yl))phenyl)-3-pyridylcarboxamide; or a pharmaceutically acceptable salt thereof.

116. (New) A compound of claim 20, wherein the compound is:

3-(4-fluorophenyl)-5-imidazol-2-yl-1H-indazole, or a pharmaceutically acceptable salt thereof.

117. (New) A compound, wherein the compound is:

3-phenyl-5-(phenylmethoxy)-1H-indazole;

(3-(4-fluorophenyl)(1H-indazol-5-yl))(phenylsulfonyl)amine;

3-(4-fluorophenyl)-1H-indazole-5-carboxylate;